VRDN
VRDN
US92790C1045
Viridian Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±68.7% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
1.1x
Above average
Volatility (5Y p.a.)
68.7% p.a.
5-Year Horizon
Max Drawdown (5Y)
-70.7%
5-Year Horizon
Sharpe Ratio
0.00
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -14.1%
3 Years 66.8% -60.6% 0.11 +9.8%
5 Years 68.7% -70.7% 0 +2.5%
10 Years 133.6% -97.9% -0.14 -16.1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (68.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -97.9% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
5 ISS Score: 5 / 10
Audit Risk
5 ISS Score: 5 / 10
Board Risk
2 ISS Score: 2 / 10
Short Ratio
15.89
ende